Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Anticholinergic

Therapeutic area intelligence for Anticholinergic with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 2

Companies

Edenbridge Pharmaceuticals →

Mankind Pharma →

Assets

Recent signals(7)

RegulatoryAugust 9, 2026

FDA Approval Process Update for Glycopyrrolate (ANDA 216910)

The FDA has an active application for Glycopyrrolate (ANDA 216910) submitted by Quagen, currently under standard review.

StrategyAugust 5, 2026

FDA Grants Approval for Atropine Sulfate ANDA219996

The FDA has granted approval for ANDA219996, a generic version of Atropine Sulfate, submitted by Gland.

RegulatoryAugust 5, 2026

FDA grants AP status for Atropine Sulfate ANDA218148 by Mankind Pharma

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA) 218148 for Atropine Sulfate submitted by Mankind Pharma.

RegulatoryJuly 27, 2026

FDA Approves Atropine Sulfate Application ANDA219013 by Edenbridge Pharms

The FDA has approved the ANDA219013 application for Atropine Sulfate submitted by Edenbridge Pharms.

StrategyJuly 19, 2026

FDA Grants Approval for Glycopyrrolate ANDA216910 by Quagen

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Glycopyrrolate submitted by Quagen.

RegulatoryJuly 13, 2026

FDA Grants AP Status for Atropine Sulfate ANDA218148 by Mankind Pharma

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA218148) for Atropine Sulfate submitted by Mankind Pharma.

RegulatoryJuly 4, 2026

FDA Grants Approval for Atropine Sulfate ANDA219013 by Edenbridge Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219013 for Atropine Sulfate submitted by Edenbridge Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.